<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300728</url>
  </required_header>
  <id_info>
    <org_study_id>IVIG-KILE-032010</org_study_id>
    <nct_id>NCT01300728</nct_id>
  </id_info>
  <brief_title>Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment</brief_title>
  <acronym>MCI</acronym>
  <official_title>A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutter Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutter Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of
      progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous
      immunoglobulins (IVIG) could potentially reduce the risk of progression to Alzheimer disease.

      This study will evaluate the efficacy of intravenous immunoglobulin in patients with MCI over
      24 months after the first infusion. This study will also document conversion from MCI to
      Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening procedures at visit 1 will take place up to 28 days prior to Visit 2 (Day 1)
      dosing. Screening labs and assessments will be performed during the screening period. A brain
      MRI will be obtained as standard of care within 6 months prior to the screening period. The
      first dose of study drug is administered on Day 1. Visits 2 through 6 have a ±1 day window
      and occur every 14 days over two months. The investigator will determine if a subject is
      suitable to continue following the missed infusion. Visits 7 through 12 (Month 4 through
      Month 24) have a ±7 day window.

      All study screening data from Visit 1 including laboratory results must be reviewed for study
      eligibility prior to receiving first dose of study drug. Visit 2 physical exams and
      neurological exams prior to infusion may occur within 72 hours prior to the first infusion.
      Prior to infusion, a review of concomitant medications and adverse events takes place to
      ensure that no excluded medications have been added or medication discontinued or dose
      changed that were required to have been stable. If the subject continues to be eligible for
      enrollment, the subject will be randomized, infused with study medication and will remain in
      the infusion clinic for at least 4 hours following the start of the infusion for safety
      assessments on Visit 2 (Day 1).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI</measure>
    <time_frame>Baseline, 12, and 24 month MRI evaluation</time_frame>
    <description>Change in ventricular volumetric as measured by MRI at baseline, 12, and 24 months following the first infusion of either 0.4 g/kg NewGam or 0.9% saline solution(placebo) every 14 days x 5.
Participants will also be classified as early MCI (EMCI) if baseline CDR-SB is less than 1.5, and late MCI (LMCI) if CDR-SB is greater than or equal to 1.5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD)</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>The National Institute of Neurological and Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer's Criteria were proposed in 1984 by NINCDS-ADRDA criteria for diagnosing Alzheimer Disease and Clinical Dementia Rating (CDR) will be used to determine conversion from a-MCI to AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer Signature</measure>
    <time_frame>Baseline to 24 months following infusion</time_frame>
    <description>Mean ventricular volume (cubic centimeters) in patients with positive cerebrospinal fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer signature at 24 months following infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cognitive Performance at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>12 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cognitive Performance at 24 Months</measure>
    <time_frame>24 month</time_frame>
    <description>24 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>intravenous immunoglobulin (IVIG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVIG (NewGam 10%)at 0.4 g/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NewGam 10% IVIG</intervention_name>
    <description>Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
    <arm_group_label>intravenous immunoglobulin (IVIG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 50 to &lt; 85 years old.

          2. Diagnosis of Mild Cognitive Impairment, Amnestic type (single or multi domain)
             according to Petersen criteria (Appendix B) and supported by a CDR score of 0.5.

          3. Mini-Mental State Examination (MMSE) score of 24-30, inclusive.

          4. Rosen Modified Hachinski Ischemic score ≤ 4.

          5. Willing to consent to Apolipoprotein E (ApoE) testing and agree to disclose
             Apolipoprotein E4 (ApoE4) status. Previous ApoE testing will be accepted.

          6. Receiving stable doses of medication(s) for the treatment of non-excluded medical
             condition(s) for at least 30 days prior to screening.

          7. Ability to attend all clinical visits and have an informant capable of accompanying
             the subject on specific clinic visits for two years or the duration of the study.

          8. The subject's collaborative informant (support person) must be someone who has known
             the subject for at least 4 years; agrees to have at least 2 separate communications
             with the study participant per month for the duration of the study (one of these
             communications must be in person); and attends and completes the CDR interview at 8
             study visits along with the subject.

          9. Fluency in English and evidence of adequate premorbid intellectual functioning.

         10. Adequate manual dexterity, visual, and auditory abilities to perform all aspects of
             the cognitive and functional assessments.

         11. Venous access suitable for repeated infusion and phlebotomy.

        Exclusion criteria:

          1. Has significant neurological disease, other than a-MCI that may affect cognition.

          2. History of clinically evident stroke or history of clinically significant carotid or
             vertebrobasilar stenosis or plaque.

          3. History of seizures, excluding febrile seizures in childhood.

          4. Brain MRI shows moderate or severe cortical or hippocampal atrophy.

          5. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, CSF
             shunts, claustrophobia, metal fragments or foreign objects in the eyes, skin, or body
             that would contraindicate a brain MRI scan.

          6. Current presence of a clinically significant major psychiatric disorder according to
             the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition (DSM-IV-TR).

          7. History of cancer within the last 5 years, with the exception of nonmetastatic basal
             cell carcinoma, and squamous cell carcinoma of the skin.

          8. Uncontrolled hypertension (diastolic BP&gt; 100 mmHg or systolic BP&gt; 160 mmHg, sitting).

          9. History or evidence of any clinically significant autoimmune disease or disorder of
             the immune system (eg., Crohn's Disease, Rheumatoid Arthritis)

         10. Women of childbearing potential.

         11. Weight greater than 120 kg (264 lbs).

         12. Excessive smoking defined as more than 20 cigarettes per day.

         13. History of alcohol or drug dependence or abuse as defined by DSM-IV criteria within
             the last 2 years.

         14. Severe liver or kidney disease verified by the PI review of alanine aminotransferase
             (ALT), aspartate aminotransferase (AST) and creatinine.

         15. Known coagulopathy, thrombosis, or low platelet count.

         16. Known deficiency to Immunoglobulin A (IgA).

         17. Positive serology for Hepatitis B or C, or HIV.

         18. Concurrent or prior treatment with cholinesterase inhibitors and/or memantine, or
             Axona for cognitive enhancement. Exceptions (e.g. brief exposure to one of these
             medications) may be authorized if agreed upon by PI and sub-I.

         19. Concurrent use of anticholinergic drugs including diphenhydramine.

         20. Current use of anticonvulsant drugs for seizures, antiparkinson drugs, anticoagulant
             medications (except the use of aspirin 325 mg/day or less, plavix, aggrenox, and
             persantine but not for stroke).

         21. Concurrent use of opioid pain relievers and related synthetic derivatives.

         22. Use of experimental medications for AD or any other investigational medications or
             devices within 60 days prior to screening or within 5 half-lives of use of such a
             medication prior to screening, whichever is longer.

         23. Prior treatment with IVIG or other experimental immunotherapeutic or vaccine for MCI
             or AD, or prior treatment with a biological product for the treatment of a-MCI or AD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Kile, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutter Neuroscience Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21.</citation>
    <PMID>18294736</PMID>
  </reference>
  <results_reference>
    <citation>Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):106-112. doi: 10.1136/jnnp-2015-311486. Epub 2015 Sep 29.</citation>
    <PMID>26420886</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>August 8, 2015</results_first_submitted>
  <results_first_submitted_qc>March 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2016</results_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutter Health</investigator_affiliation>
    <investigator_full_name>Shawn Kile, M.D.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Intravenous immunotherapy</keyword>
  <keyword>Conversion to Alzheimer Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Fifty-two participants were randomized; however, 2 participants in the IVIG group did not complete the series of 5 infusions, and 1 placebo participant was excluded due to significant language symptoms which were a barrier to cognitive testing. This resulted having a data set consisting of a total of 49 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Immunoglobulin (IVIG)</title>
          <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
        </group>
        <group group_id="P2">
          <title>Saline Solution</title>
          <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Immunoglobulin (IVIG)</title>
          <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
        </group>
        <group group_id="B2">
          <title>Saline Solution</title>
          <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.26" spread="7.91"/>
                    <measurement group_id="B2" value="72.40" spread="7.36"/>
                    <measurement group_id="B3" value="72.32" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Cognitive Performance</title>
          <description>12 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>MMSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.75" spread="2.15"/>
                    <measurement group_id="B2" value="26.44" spread="2.6"/>
                    <measurement group_id="B3" value="26.59" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADAS-cog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.63" spread="4.23"/>
                    <measurement group_id="B2" value="10.29" spread="5.68"/>
                    <measurement group_id="B3" value="10.46" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDR_SB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.96" spread="0.95"/>
                    <measurement group_id="B2" value="1.58" spread="0.90"/>
                    <measurement group_id="B3" value="1.78" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI</title>
        <description>Change in ventricular volumetric as measured by MRI at baseline, 12, and 24 months following the first infusion of either 0.4 g/kg NewGam or 0.9% saline solution(placebo) every 14 days x 5.
Participants will also be classified as early MCI (EMCI) if baseline CDR-SB is less than 1.5, and late MCI (LMCI) if CDR-SB is greater than or equal to 1.5.</description>
        <time_frame>Baseline, 12, and 24 month MRI evaluation</time_frame>
        <population>Annualized Percent Change in ventricular volume (APCV) at 12 and 24 months was computed as:
((12 or 24 month volume) - (Baseline volume))/(Baseline volume)/(Time (years) between Baseline and 12 or 24 month visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin (IVIG)</title>
            <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI</title>
          <description>Change in ventricular volumetric as measured by MRI at baseline, 12, and 24 months following the first infusion of either 0.4 g/kg NewGam or 0.9% saline solution(placebo) every 14 days x 5.
Participants will also be classified as early MCI (EMCI) if baseline CDR-SB is less than 1.5, and late MCI (LMCI) if CDR-SB is greater than or equal to 1.5.</description>
          <population>Annualized Percent Change in ventricular volume (APCV) at 12 and 24 months was computed as:
((12 or 24 month volume) - (Baseline volume))/(Baseline volume)/(Time (years) between Baseline and 12 or 24 month visit)</population>
          <units>percent change per participant year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>APCV Baseline to12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="3.91"/>
                    <measurement group_id="O2" value="8.14" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APCV Baseline to 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.26" spread="4.17"/>
                    <measurement group_id="O2" value="7.08" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD)</title>
        <description>The National Institute of Neurological and Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer's Criteria were proposed in 1984 by NINCDS-ADRDA criteria for diagnosing Alzheimer Disease and Clinical Dementia Rating (CDR) will be used to determine conversion from a-MCI to AD.</description>
        <time_frame>Baseline to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin (IVIG)</title>
            <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD)</title>
          <description>The National Institute of Neurological and Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer's Criteria were proposed in 1984 by NINCDS-ADRDA criteria for diagnosing Alzheimer Disease and Clinical Dementia Rating (CDR) will be used to determine conversion from a-MCI to AD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer Signature</title>
        <description>Mean ventricular volume (cubic centimeters) in patients with positive cerebrospinal fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer signature at 24 months following infusion</description>
        <time_frame>Baseline to 24 months following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin (IVIG)</title>
            <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer Signature</title>
          <description>Mean ventricular volume (cubic centimeters) in patients with positive cerebrospinal fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer signature at 24 months following infusion</description>
          <units>cubic centimeters (cc)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aβ42 (cc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.00" spread="96.55"/>
                    <measurement group_id="O2" value="353.41" spread="112.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tau (cc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.47" spread="58.65"/>
                    <measurement group_id="O2" value="96.18" spread="65.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-tau (cc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.59" spread="19.90"/>
                    <measurement group_id="O2" value="39.47" spread="30.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cognitive Performance at 12 Months</title>
        <description>12 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin (IVIG)</title>
            <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cognitive Performance at 12 Months</title>
          <description>12 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mini Mental State Exam (MMSE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.04" spread="3.76"/>
                    <measurement group_id="O2" value="25.38" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alzheimer's Disease Assessment Scale (ADAS-Cog)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.03" spread="6.66"/>
                    <measurement group_id="O2" value="11.00" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Dementia Rating Sum of Boxes (CDR-SB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.63"/>
                    <measurement group_id="O2" value="2.65" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cognitive Performance at 24 Months</title>
        <description>24 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
        <time_frame>24 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin (IVIG)</title>
            <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cognitive Performance at 24 Months</title>
          <description>24 month cognitive performance in treatment (IVIG/placebo) is measured by:
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)
Scale from 0 to 85 (0 is best cognitive performance)
Score is the sum of 12 sub-scales.
Mini Mental State Exam (MMSE)
Scale from 0 to 30 (30 is best cognitive performance)
Score is the sum of 11 sub-scales.
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Scale is 0 to 18 (0 is best cognitive performance)
Score is the sum of 6 sub-scales</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mini Mental State Exam (MMSE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" spread="4.91"/>
                    <measurement group_id="O2" value="24.46" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alzheimer's Disease Assessment Scale (ADAS-Cog)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.39" spread="10.55"/>
                    <measurement group_id="O2" value="13.25" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Dementia Rating Sum of Boxes (CDR-SB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="3.48"/>
                    <measurement group_id="O2" value="3.37" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Immunoglobulin (IVIG)</title>
          <description>IVIG (NewGam 10%)at 0.4 g/kg
NewGam 10% IVIG: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.</description>
        </group>
        <group group_id="E2">
          <title>Saline Solution</title>
          <description>0.9% saline solution
Placebo: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Low grade fever</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Severity = moderate</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Severity = moderate</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Severity = mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shawn Kile, MD</name_or_title>
      <organization>Sutter Neurology Medical Group</organization>
      <phone>(916) 454-6850</phone>
      <email>KileS@sutterhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

